University of California San Francisco, San Francisco, CA
Evan Justin Walker , Amie Blanco , Julia C. Carnevale , Pelin Cinar , Eric Andrew Collisson , Margaret A. Tempero , Andrew H. Ko
Background: Germline genetic testing is now universally recommended for patients (pts) with pancreatic ductal adenocarcinoma (PDAC) for purposes of both familial screening and therapeutic guidance. Treatment selection can be further informed by tumor molecular profiling (TMP) to identify targetable somatic alterations in pts with advanced disease, but this is inconsistently applied. Determination of the rate of actionable findings identified with TMP after germline testing, which we term marginal diagnostic benefit, may inform practice patterns and workflow in this patient population. Methods: This retrospective analysis included all pts with PDAC who underwent germline testing and TMP at UCSF over a 4-yr period. Medical records were reviewed for demographics, disease-specific data, and germline testing/TMP clinical reports. Alterations classified as ‘pathogenic’ or ‘likely pathogenic’ were included, and were deemed ‘actionable’ if there was clinical or preclinical evidence of benefit from targeted therapy in any cancer, as previously described. Results: From 1/2016-1/2020, 144/738 (20%) UCSF pts with PDAC completed both germline testing and TMP. Germline testing identified actionable pathogenic alterations in 10 (7%). TMP confirmed 8/10 of these alterations and identified 3 additional therapeutic targets. Among the 134 pts without actionable germline findings, TMP identified 45 new therapeutic targets in 41 (31%) pts, increasing the overall rate of actionable findings from 7% to 35%. Most (35/58, 60%) actionable alterations involved genes associated with the Homologous Recombination DNA Damage Repair (HR-DDR) pathway (Table). 80% of pts with HR-DDR pathway alterations (9/10 germline, 19/25 somatic) received platinum-based chemotherapy. Four pts were treated with targeted therapy based on test results: PARP-inhibitor (n = 2, germline BRCA1 and PALB2 mutations), PARP-inhibitor + ATR inhibitor (n = 1, somatic ARID1A mutation) and mTOR inhibitor (n = 1, somatic STK11 deletion). Conclusions: In this analysis, PDAC TMP after germline testing increased the detection of actionable alterations (the marginal diagnostic benefit) by five-fold. As more somatic tumor alterations become actionable with the development of targeted therapeutics, TMP is a necessary complement to germline testing to fully inform personalized treatment decisions for all pts with PDAC.
Targetable Molecular Findings | Detected by Germline Testing (n = 10) | Additional Alterations Detected by TMP (n = 48) |
---|---|---|
HR-DDR Pathway Alterations* | 10 (100%) | 25 (52%) |
PI3K/AKT/mTOR Pathway Alterations | -- | 8 (17%) |
CDK4/6 Amplifications | -- | 4 (8%) |
KRAS G12C Mutation | -- | 4 (8%) |
HER2 Amplification | -- | 3 (6%) |
BRAF Activating Mutation | -- | 1 (2%) |
RET Activating Mutation | -- | 1 (2%) |
EGFR Activating Mutation | -- | 1 (2%) |
NOTCH2 Amplification | -- | 1 (2%) |
*ARID1A (15), ATM (6), BRCA1 (5), CHEK2 (3), BRCA2 (1), BRIP1 (1), FANCA (1), MRE11A (1), PALB2 (1), RAD51C (1).
Disclaimer
This material on this page is ©2024 American Society of Clinical Oncology, all rights reserved. Licensing available upon request. For more information, please contact licensing@asco.org
Abstract Disclosures
2023 ASCO Annual Meeting
First Author: Vanessa Rosas Camargo
2022 ASCO Annual Meeting
First Author: Jamie Randall
2023 ASCO Annual Meeting
First Author: Nikolaos Tsoulos
2023 ASCO Annual Meeting
First Author: Yin Bing Wu